1. May 03, 2021

Vitritis most common intraocular inflammation after brolucizumab injection

Vitritis was the most common type of intraocular inflammation (IOI) seen in eyes treated with Intravitreal injections (IVI) of brolucizumab, according to a presentation at ARVO 2021.

In this retrospective study, researchers analyzed data from 88 patients (99 eyes) treated with intravitreal injections (IVI) of brolucizumab 6 mg/0.05 ml for neovascular age-related macular degeneration (NVAMD) over the course of 1 year. The majority of eyes (n = 89) were not treatment-naïve, and these patients experienced an average maintenance extension of 3 weeks. The average extension was 9 weeks for the 58 eyes (69.2%) that had a positive extension on maintenance. Of these 58 eyes, 24 had an injection burden reduction of ≥50% and were classified as super-responders.

Overall, IOI occurred in 8 eyes, all of which were diagnosed with vitritis, which lasted for 69 days on average. Retinal vasculitis occurred in 2 eyes with IOI, resulting in the loss of 3 letters and 10 letters, respectively. For the remaining 6 eyes without retinal vasculitis, the average vision change from IOI to the most recent visit was -2 letters, with 1 eye losing 10 letters of vision.

There was an average of 81 days from the first injection to the start of IOI, with reactions starting after 1-2 injection in the majority (n = 7) of eyes with IOI.  

The researchers suggested that risk factors for IOI included atrial fibrillation and treatment-naivety.

Hamou S, et al. A retrospective study on the use of brolucizumab for the treatment of NVAMD: A 1-year private practice experience. Presented at: ARVO 2021.